References: 1. Lajara R, Nikkel C. Poster presented at: American Association of Clinical Endocrinologists 24th Annual Scientific and Clinical Congress; May 13-17, 2015; Nashville, TN. 2. Data on File. Valeritas, Inc. August 18, 2016. 3. Lajara R, Fetchik DA, Morris TL, Nikkel C. Use of V-Go® insulin delivery device in patients with sub-optimally controlled diabetes mellitus: a retrospective analysis from a large specialized diabetes system. Diabetes Ther. 2015;6(4);531-545. 4. Rosenfeld CR, et al. Endocr Pract. 2012;18(5):660-667. 5. V-Go® Instructions for Patient Use. Valeritas, Inc. 2011. 6. Kapitza C, et al. J Diabetes Sci Technol. 2008;2(1):40-46. 7. Omer A, et al. Poster presented at: American Diabetes Association 73rd Scientific Sessions; June 21-25, 2013; Chicago, IL. Abstract 980-P. 8. Grunberger G, et al. Poster presented at: American Association of Clinical Endocrinologists 23rd Annual Scientific and Clinical Congress; May 14-18, 2014; Las Vegas, NV. Abstract 224.
Important Risk Information
If regular adjustments or modifications to the basal rate of insulin are required in a 24-hour period, or if the amount of insulin used at meals requires adjustments of less than 2-Unit increments, use of the V-Go Disposable Insulin Delivery Device may result in hypoglycemia. The following conditions may occur during insulin therapy with V-Go: hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose). Other adverse reactions associated with V-Go use include skin irritation from the adhesive pad or infections at the infusion site. V-Go should be removed before any magnetic resonance imaging (MRI) testing.